AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9868115
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine and western medicine
Trial: 9868115
Drug: Regular medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular medicine
Trial: 9868115
Drug: Peritoneal cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal cavity administration
Trial: 7869017
Drug: Radiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation treatment after October 1985
Trial: 7869017
Drug: Definitive radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Definitive radiotherapy and fat soluble chemotherapy (not utilized in earlier cases)
Trial: 2904757
Drug: Doxazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1 to 16 mg once daily)
Trial: 2904757
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 to 40 mg once daily)
Trial: 21716297
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg simvastatin daily for 6 months
Trial: 13130200
Drug: Fixed-dose fluticasone-salmeterol
RxNorm normalized name: FLUTICASONE/SALMETEROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose fluticasone-salmeterol combination (FP/S)
Trial: 13130200
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids and long-acting B2-agonists given separately (TC)
Trial: 11702613
Drug: Topical retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical retinol
Trial: 9176691
Drug: Psyllium hydrophilic
RxNorm normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium hydrophilic mucilloid (PHM) 7 gm, twice‐daily added to continuous feeding
Trial: 1382251
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Aprotinin (two subgroups with different doses)
Trial: 3891455
Drug: Oxazepam Expidet
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxazepam Expidet 30 mg
Trial: 30187935
Drug: Ticagrelor 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 0.125 mg/kg
Trial: 30187935
Drug: Ticagrelor 0.563
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 0.563 mg/kg
Trial: 30187935
Drug: Ticagrelor 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 0.75 mg/kg
Trial: 30187935
Drug: Ticagrelor 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 2.25 mg/kg
Trial: 30187935
Drug: Ticagrelor (0.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (0.125, 0.563, or 0.75 mg/kg bid)
Trial: 25164709
Drug: Dosing nomogram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing nomogram (65 patients)
Trial: 20191258
Drug: Nutritional formulation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional formulation (NF) consisting of folic acid, B12, Vitamin E, S‐adenosylmethionine, N‐acetyl cysteine, and Acetyl‐L‐carnitine
Trial: 20191258
Drug: Nutritional formulation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional formulation (NF)
Trial: 9397080
Drug: Ketoprofen 200
RxNorm normalized name: ketoprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 200 mg once daily
Trial: 30157924
Drug: 32 mg
RxNorm normalized name: caffeine 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg buprenorphine
Trial: 30157924
Drug: 64 mg
RxNorm normalized name: sulfur 64 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64 mg buprenorphine
Trial: 30157924
Drug: 96 mg
RxNorm normalized name: camphor 96 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96 mg buprenorphine
Trial: 26362831
Drug: Nebivolol (beta-blocker)
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol (beta-blocker)
Trial: 26362831
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (20 mg nebivolol/320 mg valsartan)
Trial: 17604930
Drug: Low-attenuation barium
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-attenuation barium sulphate suspension
Trial: 17604930
Drug: High-attenuation barium
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-attenuation barium sulphate preparation
Trial: 16451158
Drug: FFP (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFP (10 ml/kg)
Trial: 1437922
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate (60 mg infusion over 2 hours)
Trial: 1437922
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate (infusions over 4, 8, or 24 hours)
Trial: 1437922
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate (various infusion rates)
Trial: 1437922
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate (short infusions)
Trial: 28819922
Drug: Therapist-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-delivered cognitive behavior therapy/motivational interviewing (CBT/MI)
Trial: 25908605
Drug: Oral S-1
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral S-1 plus cisplatin (80 mg/m2/day on days 1-21 plus cisplatin 60 mg/m2 on day 8 every 4-5 weeks)
Trial: 25908605
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus cisplatin (60 mg/m2 on day 1 plus cisplatin 80 mg/m2 on day 1 every 3-4 weeks)
Trial: 17345837
Drug: fexofenadine 180
RxNorm normalized name: fexofenadine 180 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fexofenadine 180 mg
Trial: 17345837
Drug: desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: desloratadine 5 mg
Trial: 14570783
Drug: Inhalation anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anaesthesia using sevoflurane
Trial: 10781481
Drug: Chloroprocaine (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroprocaine (4.5 mg/kg)
Trial: 8635674
Drug: 100 mmol/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mmol/day sodium supplement (group 2)
Trial: 2580168
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxprenolol plus diuretic
Trial: 2580168
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus diuretic
Trial: 26351927
Drug: Enteral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral melatonin (6 mg total: 3 mg loading dose at 9 pm + six 0.5 mg doses hourly)
Trial: 26351927
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered using a similar regimen to melatonin)
Trial: 24732894
Drug: Argatroban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (10 mg intravenous twice daily for 2 days before and 3 days after stenting)
Trial: 15314593
Drug: Parent-administered visual
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-administered visual acuity testing using the EVA (Group A)
Trial: 11269893
Drug: Miglitol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (25 to 100 mg trice daily for 24 weeks)
Trial: 9017770
Drug: Enalapril-diltiazem ER
RxNorm normalized name: diltiazem / enalapril Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-diltiazem ER (dosage titrated to response, maximum of enalapril 10 mg-diltiazem ER 360 mg/day)
Trial: 9017770
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg-diltiazem ER 120 mg once/day (titrated to response)
Trial: 30681971
Drug: Melissa officinalis
RxNorm normalized name: melissa officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melissa officinalis L. based product (MO), 500 mg capsules, 2 capsules daily for 3 months
Trial: 24163425
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (control) during exercise
Trial: 17760599
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% imiquimod cream used daily in conjunction with laser therapy
Trial: 17760599
Drug: Placebo used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo used daily in conjunction with laser therapy
Trial: 7781653
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g ascorbic acid (AA) and 0.2 g pantothenic acid (PA) supplementation
Trial: 27412664
Drug: Usual routine
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual routine treatment with exercise training (n=44)
Trial: 27412664
Drug: Usual routine
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual routine treatment without training (n=20)
Trial: 26099752
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 80 mg triamcinolone and 8 ml bupivacaine 0.25%
Trial: 26099752
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 8 ml bupivacaine 0.25%
Trial: 23747802
Drug: Combined inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined inpatient physical training (aerobic + strength) for the duration of neoadjuvant chemotherapy, 3 weekly 60-70 min exercise sessions
Trial: 15577047
Drug: Raroxifene treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raroxifene treatment
Trial: 9924277
Drug: Tomato purée
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato purée (16.5 mg total lycopene)
Trial: 9924277
Drug: Fresh raw
RxNorm normalized name: Potassium/Wheat Germ 250 MG Oral Powder [NATURFRESH RAW WHEAT GERM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh raw tomato (16.5 mg total lycopene)
Trial: 9924277
Drug: Daily dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dietary portions of tomato purée (16.5 mg total lycopene) for 7 days
Trial: 9924277
Drug: Daily dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dietary portions of fresh raw tomato (16.5 mg total lycopene) for 7 days
Trial: 2682096
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g mezlocillin and 0.5 g metronidazole (one-shot dose)
Trial: 782698
Drug: BCNU maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCNU maintenance therapy
Trial: 22230353
Drug: 6% carbohydrate‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% carbohydrate‐electrolyte solution (CHO)
Trial: 22230353
Drug: Electrolyte solution
RxNorm normalized name: electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte solution (PL)
Trial: 20049949
Drug: pH-dependent release
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-dependent release formulation of mesalamine at 2.4 g/day
Trial: 20049949
Drug: Time-dependent release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-dependent release formulation of mesalamine at 2.25 g/day
Trial: 20049949
Drug: pH-dependent release
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-dependent release formulation of mesalamine
Trial: 20049949
Drug: Time-dependent release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-dependent release formulation of mesalamine
Trial: 19265453
Drug: artesunate monotherapy
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: artesunate monotherapy 7 d (AS7)
Trial: 12093428
Drug: Glutamine-supplemented total
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-supplemented total parenteral nutrition
Trial: 15613202
Drug: Conventional pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacotherapy
Trial: 31899379
Drug: Salvadora persica
RxNorm normalized name: SALVADORA PERSICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvadora persica (SP) gel application
Trial: 31899379
Drug: Professionally administered
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professionally administered plaque removal (PAPR)
Trial: 26159015
Drug: Qingfei Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingfei Decoction (QD) treatment group
Trial: 24631099
Drug: Automated reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated reminder messages for vaccine doses two and three
Trial: 23066765
Drug: Discharge Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge Preparation Program (DPP)
Trial: 19776405
Drug: Escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated dose of daunorubicin (90 mg/m²) plus cytarabine (200 mg/m² for 7 days)
Trial: 19776405
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of daunorubicin (45 mg/m²) plus cytarabine (200 mg/m² for 7 days)
Trial: 17096464
Drug: Both cognitive-behavioral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both cognitive-behavioral group therapy and clinical case management
Trial: 12631177
Drug: Enamel matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel matrix proteins (EMP) treatment
Trial: 11085964
Drug: Acetylcholine (intra-arterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine (intra-arterial infusion)
Trial: 11085964
Drug: Verapamil (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (calcium channel blocker)
Trial: 8857879
Drug: Indwelling percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indwelling percutaneous intramuscular electrode composed of helically coiled Teflon‐coated rope stranded from 19 hard drawn wires of SUS 316L stainless steel (SES 114)
Trial: 8857879
Drug: Indwelling percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indwelling percutaneous intramuscular electrode
Trial: 1352732
Drug: Esmolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (2 or 3 mg.kg-1)
Trial: 1352732
Drug: Esmolol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (3 mg.kg-1)
Trial: 1352732
Drug: Esmolol and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol and topical laryngeal anaesthesia
Trial: 30361250
Drug: Sertraline 25‐100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 25‐100 mg (titrated upwards over 9 days)
Trial: 28916591
Drug: Computer-guided glucose
RxNorm normalized name: ACCU-CHEK GUIDE (GLUCOSE) METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-guided glucose infusion rate (GIR) with continuous glucose monitoring (CGM)
Trial: 25792176
Drug: Magnesium 30
RxNorm normalized name: Magnesium 30mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium 30 mg/kg
Trial: 23385272
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection plus physiotherapy
Trial: 19483418
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose of docetaxel (40 or 50 mg/m²)
Trial: 19483418
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of docetaxel (60 mg/m²)
Trial: 17089233
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg i.v. at the end of the operation followed by 8 mg b.i.d., i.v. for 24 hours
Trial: 16283275
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral gemfibrozil twice daily for 2 days
Trial: 16283275
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral gemfibrozil
Trial: 8432299
Drug: Captopril 6.25
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 6.25 mg every 6 h on the first day and 12.5 mg qid on the second day if MAP > or = 70 mmHg (group 1)
Trial: 22738092
Drug: Total intravenous-plus-oral
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous-plus-oral regimen (LEV)
Trial: 22738092
Drug: Total intravenous-plus-oral
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous-plus-oral regimen (PHT)
Trial: 21705281
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 or 15 mg/kg intravenously (I.V.) on day 1, every 21 days plus investigator's choice of agents (pemetrexed, docetaxel, or erlotinib) for second-line and subsequent lines of treatment.
Trial: 21705281
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of agents alone indicated for use in second-line and subsequent lines of treatment, but no further bevacizumab treatment.
Trial: 18562414
Drug: Citalopram (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (selective serotonin reuptake inhibitor)
Trial: 12922956
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy including glucocorticoids
Trial: 12922956
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (2001 cohort with early RA)
Trial: 8638787
Drug: Ketorolac 60
RxNorm normalized name: ketorolac 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 60 mg IV 15 min after skin incision
Trial: 1999742
Drug: Counseling plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling plus prescription of nicotine-containing gum (Nicorette)
Trial: 31504608
Drug: 500 IU
RxNorm normalized name: Vitamin E 500 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 IU per steer daily (MED)
Trial: 31504608
Drug: 1,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 IU per steer daily (HIGH)
Trial: 30133134
Drug: Cinnamyl Isobutyrate
RxNorm normalized name: isostearyl isobutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamyl Isobutyrate (CIB) 0.45 mg in 75 g glucose solution
Trial: 30133134
Drug: Control (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (75 g glucose solution)
Trial: 23185753
Drug: Fuzheng Jianpi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Jianpi Decoction (FJD) combined with chemotherapy
Trial: 12297711
Drug: Thermal balloon
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal balloon endometrial ablation therapy
Trial: 7602060
Drug: Interferon-alpha 2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2a (IFN-alpha 2a) at an induction dose of 6 MIU thrice weekly for 3 months, followed by 3 MIU thrice weekly for an additional 3 months as maintenance therapy.
Trial: 227340
Drug: Long-acting fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting fluphenazine decanoate with social therapy (ST)
Trial: 227340
Drug: Oral fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluphenazine hydrochloride
Trial: 11417777
Drug: 4-mg gum
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-mg gum
Trial: 9327189
Drug: soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soluble aspirin
Trial: 9327189
Drug: plain aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plain aspirin
Trial: 9327189
Drug: enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enteric-coated aspirin granules
Trial: 9327189
Drug: mouth-dispersible aspirin
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mouth-dispersible aspirin
Trial: 3259087
Drug: Propofol 1
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg/kg intravenous bolus for induction and 0.1 mg/kg/minute continuous infusion for maintenance